LGC completes first FDA inspection of its Sandwich laboratory
On 22 June, LGC’s laboratories in Sandwich, UK, completed a three-day inspection by the US Food and Drug Administration (FDA). This was the laboratory’s first inspection by the FDA and was an extensive audit focusing on GMP compliance.
The site specialises in CMC materials science for pharmaceutical and biopharmaceutical companies and forms an integral part of LGC’s bioanalytical and analytical drug development services business.
David Griffiths, Managing Director, Laboratory and Managed Services, LGC, said, “This FDA inspection marks a significant milestone for our drug development services team and our customers. We were delighted to have such positive and constructive dialogue with the inspector during the audit. Our team has swiftly addressed the single observation documented, further reinforcing our ongoing commitment to the highest quality science and service.”